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THE DOS AND DON’TS IN PAYER COMMUNICATION. A QUALITATIVE 
RESEARCH ACROSS FIVE EUROPEAN COUNTRIES
Guhl AK1, Gbenedio T1, Vekaria R1, Shepelev J1, Kolominsky-Rabas P2
1GfK HealthCare, London, UK; 2Centre for Health Technology Assessment (HTA) and 
Public Health (IZPH), University of Erlangen-Nurnberg, Erlangen, Germany
OBJECTIVES: National authorities across Europe implement both controls and incen-
tives to inﬂ uence the supply and demand of pharmaceuticals and medical devices. 
Today, greater emphasis is placed on increasing efﬁ ciency in the resources spent on 
health care via tighter controls on pricing and reimbursement regulations. Companies 
increasingly face the challenge to communicate their value propositions towards 
payers adequately. We investigated in 5 European countries (D,F,UK,NL,I) if compa-
nies meet payers expectations and also asked for suggestions how companies could 
improve. METHODS: A questionnaire was developed, validated and translated into 
the local language. Some questions were speciﬁ c to the national health care system. 
In total 20 face—to- face interviews were conducted with decision makers at various 
levels. All interviews were recorded. RESULTS: The expectations among payers across 
Europe with regard to industry communication vary widely. The emphasis lies in the 
presentation of scientiﬁ c data with more focus on clinical rather than economic data. 
Some of the interviewees revealed some poor examples and mistakes made by com-
panies, others gave us insights into what an “ideal” communication platform with the 
industry could look like on a national level. CONCLUSIONS: The results showed 
that even in Europe there is a huge variety how to communicate with payers from an 
industry perspective. Cultural and health care system speciﬁ cs need to be taken into 
account to develop successful payer communication strategies.
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SENSE OF COHERENCE—AS MEDIATING FACTOR IN REMAINING 
EMPLOYED IN HEALTH CARE PROFESSION
Roznár J, Oláh A, Tóth Á, Betlehem J, Boncz I, Müller Á, Jeges S
University of Pécs, Pécs, Hungary
OBJECTIVES: To prove the hypothesis that sense of coherence has a signiﬁ cant 
mediating role in keeping career in health care. METHODS: Our database: students 
in the programme of nursing (n = 203) versus randomly selected sample of students 
studying in other programmes (n = 196); and health care professionals (n = 96) vs. a 
randomly selected sample of people employed elsewhere but not in health care (n = 
741). Anonym self-completed questionnaires were used: Antonovsky’s SOC scale vali-
dated on Hungarian sample; Hennenhofer’Heil’s vegetative lability test and a health 
self-estimation scale. Used statistical methods: variance analysis and multinomial 
logistic regression. RESULTS: According to the ANOVA and post hoc tests, global 
sense of coherence of students studying in health care programmes was signiﬁ cantly 
lower (p < 0,001) than that of those students studying in other programmes; the results 
of health care professionals did not signiﬁ cantly differ from the control sample. The 
highest SOC were scored by those health care professionals who were studying besides 
working. According to the indicators of state of health the health self-estimation of 
health care students was signiﬁ cantly lower than that of those participating in other 
programmes (based on the post hoc t-tests, P < 0,05) however, between the two 
samples of employees there was no signiﬁ cant difference. We have proved with mul-
tinominal logistic regression models that SOC and the state of health are mostly 
inﬂ uenced by physical activity. CONCLUSIONS: Our hypothesis has been conﬁ rmed 
by the results. Relatively more health care students with a high SOC are employed in 
the health care. This could be the explanation for the phenomenon that health care 
students have lower SOC compared to those studying in other programmes but in 
both groups of employees there is no difference concerning SOC. This proves the 
importance of enhancement of SOC among health care students, which can be primar-
ily achieved by augmenting physical activity.
PHP97
TRAINING OF PHARMACEUTICAL SALES REPRESENTATIVES IN 
REGARD TO CHANGES IN HEALTH CARE POLICY IN GERMANY
Benkert D1, Saile C1, Schauer S1, Kossmann B1, Wasem J2, Aidelsburger P1
1CAREM GmbH, Sauerlach, Germany; 2University of Duisburg-Essen, Essen, Germany
OBJECTIVES: Due to rapid changes in health policy in Germany there is a need for 
actors in health care system for constant training about the system. Aim of the present 
study is to assess different teaching methods using the example of training pharma-
ceutical sales representatives concerning effectiveness assessment as performed by 
several institutions in Germany. METHODS: Two learning approaches are compared. 
“Health Consultant (HC)” is a training program teaching pharmaceutical sales rep-
resentatives in health policy topics using traditional training methods like talks and 
discussions. Second approach is an e-learning program. Participants were interviewed 
by questionnaires about their learning preferences. RESULTS: Evaluation of the HC 
training program shows, that the traditional teaching method is well accepted. Learn-
ing success was conﬁ rmed by subjective valuation. Most participants report a demand 
for a more ﬂ exible and individual learning approach that is compatible to their every-
day work. E-learning programmes could meet these criteria. CONCLUSIONS: Further 
studies are necessary to evaluate the learning success of both methods. Evaluation 
instruments are already developed. The dimensions that should be included are moti-
vation, workloads and structure of learning unit.
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COST-EFFECTIVENESS METHODOLOGIES OF STRATEGIES THAT AIM 
TO CHANGE THE BEHAVIOUR OF HEALTH CARE PROFESSIONALS
Kusel J, Costello S, Brooks-Rooney C, Hamer N
Costello Medical Consulting Ltd, Cambridge, UK
BACKGROUND: As the cost-effectiveness of strategies that aim to change the behav-
iour of physicians has not been widely studied, it is unclear whether a standard 
methodology is being utilised for measuring cost-effectiveness in this situation. 
OBJECTIVES: To review the current literature on the methodologies used in cost-
effectiveness evaluations of behaviour change policies for health care professionals. 
METHODS: A search of the MEDLINE database and of reference lists was performed 
up to May 2010. RESULTS: Twelve relevant evaluations, from ten publications, were 
identiﬁ ed; two discussed costs and beneﬁ ts separately and were therefore not classed 
as true cost-effectiveness evaluations. Of the remaining ten, seven were based on 
randomised controlled trials, two used a model without empirical data and one was 
a prospective cohort study. Eight of the ten evaluations utilised health outcomes as 
the main effectiveness measure, ﬁ ve of which used life-years (LY) or quality-adjusted 
LYs gained. The ten cost-effectiveness evaluations measured: implementation cost per 
LY or health outcome gained (6); total policy cost per LY gained (2); implementation 
cost per percent change in prescribing (1) and percent change in health outcome per 
pound (1). Nine took a health care provider perspective; one took a societal perspec-
tive that included patient expenditure. There was no agreement between the ten evalu-
ations as to whether physician time should be included in the cost analysis or not (yes 
(3), no (4), not stated (3)). Only two evaluations considered a time frame beyond 1 
year and took into account that future implementations would be required to maintain 
the behaviour change. Discounting of values was utilised by these evaluations (3% 
per year), and by 1 other study (percent not stated). CONCLUSIONS: More robust 
evaluations are required, with health outcomes assessed as LYs for comparison pur-
poses. Future evaluations must consider timeframe, discounting, societal costs and 
costs due to physician time.
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FIRST-IN-THERAPY PRODUCTS AND REQUIREMENTS FOR 
SUCCESSFUL HTA ASSESSMENT
Xia AD, Oraro T
Heron Evidence Development Ltd., London, UK
OBJECTIVES: To determine the necessary requirements of a ﬁ rst-in-therapy product 
to support positive HTA review. METHODS: An initial broad search was conducted 
to identify ﬁ rst-in-therapy products launching in recent years into disease areas with 
no alternative treatments. The products identiﬁ ed were eculizumab for paroxysmal 
nocturnal hemoglobinuria (PNH), pregabalin for ﬁ bromyalgia, vigabatrin for infantile 
spasms, tetrabenazine for tardive dyskinesia (TD) and chorea of Huntington’s disease, 
pirfenidone for idiopathic pulmonary ﬁ brosis (IPF), and amifampridine for Lambert-
Eaton myasthenic syndrome (LEMS). These products were then examined within 
NICE, SMC, NCPE, PBAC and CADTH websites, and information collated on clinical 
endpoints, HTA comparators and assessment outcomes to provide an understanding 
of the requirements of ﬁ rst-in-therapy products for positive review. RESULTS: Of the 
drugs selected, 4 were assessed by HTA bodies. Due to a lack of alternative therapies, 
all but one product assessed carried out trials against placebo. Clinical endpoints were 
based either on metrics agreed upon by KOLs, quality of life measures, or both. Out 
of the seven drugs studied, only vigabatrin received positive recommendation due to 
strong trial data and inclusion of an active symptomatic comparator. a number of 
ﬁ rst-in-therapy products were actually rejected by HTAs in select countries. Pregabalin 
was rejected due to unconvincing trial data despite a favourable cost per QALY and 
eculizumab was rejected due to too high an incremental cost per QALY. CONCLU-
SIONS: We can conclude that based on the products assessed, ﬁ rst-in-therapy products 
do not typically receive special consideration when assessed by HTA bodies. An active 
comparator, use of recognized endpoints and the quality of data remain as important 
requirements for positive review. Furthermore, demonstrated cost-effectiveness is 
required even in a novel disease area, thus, it will be necessary to evaluate this earlier 
in development. More focused studies need to be carried out to ascertain this trend 
on a country-by-country basis. 
HEALTH CARE USE & POLICY STUDIES – Health Technology Assessment 
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EVALUATION OF ACCEPTANCE AND REJECTION RATES OF ORPHAN 
DRUGS ACROSS SIX HTA AGENCIES
Jäkel A1, Alnwick K2
1Heron Evidence Development Ltd, Stopsley, UK; 2Heron Evidence Development Ltd, 
London, UK
OBJECTIVES: Many orphan drugs receive market authorization, however an assess-
ment of cost-effectiveness is usually required before these drugs can be reimbursed. 
Recent research has explored the differences between HTA bodies in their rates of 
acceptance/rejection of orphan drugs. The objective of this study was to consider the 
relative weight of economic and clinical reasons for rejecting orphan drug submissions 
to HTA agencies. METHODS: Six HTA websites (NICE, SMC, NCPE, CEDAC, 
PBAC, AWMSG) were searched for summary guidance on 71 licensed orphan drugs 
identiﬁ ed from a search of the Orphanet website. RESULTS: Of 53 total non-approved 
